Talat Imran - 27 Sep 2026 Form 4 Insider Report for Rani Therapeutics Holdings, Inc. (RANI)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: RANI
Reported as of: 27 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Sep 2026, 16:42:37 UTC
Prior SEC filing: 21 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Talat Imran

Key filing fact

Talat Imran filed Form 4 for Rani Therapeutics Holdings, Inc. (RANI) on 29 Sep 2026.

Key facts

This page summarizes Talat Imran's Form 4 filing for Rani Therapeutics Holdings, Inc. (RANI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 29 Sep 2026, 16:42.

Change

Previous filing in this sequence was filed on 21 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001869579 Primary reporting owner

Imran Talat

Relationship: Chief Executive Officer, Director
Address: C/O RANI THERAPEUTICS LLC, 2051 RINGWOOD AVE, SAN JOSE
Signature: /s/ Talat Imran
Signature date: 29 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RANI transaction

Class A Common Stock

Tax liability

Transaction value
Shares: -7,928
Change %: -1.7%
Price: $0.7592^*
Shares after: 461,808
Date: 27 Sep 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares withheld by and surrendered to the Issuer to satisfy tax withholding obligations in connection with the settlement and release of the restricted stock units.